2018-04-008 - Ocular Brachytherapy - Application of nanoparticles in ocular brachytherapy
Contacts
LT
Acronim & Gínjol codes
Ocular Brachytherapy
2018-04-008
Main technology offer
New technical development in ocular brachytherapy so as to minimize radiation collateral damage. Application of intravitreal iron oxide nanoparticles in order to form an external shield over the tumor surface
Ownership
L'Hospitalet de Llobregat, Spain
2004
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
The governance of the project is being conducted by public institution, guaranteeing its transparency. Additionally, the production of nanoparticles would respect the environmental concerns
offer a solution to overcrome side effects of radiotherapy
Market Data
Episcleral brachytherapy is the most widely used procedure for the treatment of uveal melanoma. Although this technique preserves the eyeball. The problem of the treatment is the collateral damages to the healthy ocular tissue
0
0
0
The business model is based in a co-development with an interested party or even license the technology
The present technology may involve a radical change in the evolution of patients suffering from uveal melanoma. It has been designed to protect the healthy eye structures from ionizing radiation, so that adequate treatment doses may be applied with less risk and severity of side effects. This technology will increase the array of tumors capable to be treat by standard brachytherapy.
The global brachytherapy market size was valued at around USD 312.2 million in 2017 andexpected to grow at a CAGR of over 4.76 % over the forecasted period.
Funding
The project is looking for funds to continue with the development and to explore the MoA and toxicology of the technology
Public funding and/or co-development funds
Study the feasability and toxicology of the technology
Technology Status
The novelty arises from application of intravitreal iron oxide nanoparticles to form an external shield covering the tumor surface. The nanoparticles are driven to the correct intraocular location by an externally-placed magnet adapted to the radioactive plaque and attached to the sclera over the tumor base. The formation of the nanoparticles shield would minimize ocular radiation-induced adverse events
Low target population. Market of interest, high competence
Once we have the validation in rabbits, we will look for companies of interest
Under patentability study
project pending of patentability
Additional information
Patents: WO2013011176A8 ; PCT/ES2012/070474 - Apr 17th, 2014 - Status: Granted -
The formation of the nanoparticles shield would minimize ocular radiation adverse events. Iron nuclei are expected to partially block the spilling radiation to healthy intraocular tissues. Additionally, it is presumed that particles contacting the tumor surface act as radiosensitizers providing a homogenization of the absorbed dose in the tumor.